Exome sequencing study in patients with multiple sclerosis reveals variants associated with disease course
Creators: name: Gil-Varea, Elia
name: Urcelay, Elena
name: Vilariño-Güell, Carles
name: Costa, Carme
name: Midaglia, Luciana
name: Matesanz, Fuencisla
name: Rodríguez-Antigüedad, Alfredo
name: Oksenberg, Jorge
name: Espino-Paisan, Laura
name: Dessa Sadovnick, A.
name: Saiz, Albert
name: Villar, Luisa M
name: García-Merino, Juan A
name: Ramió-Torrentà, Lluís
name: Triviño, Juan C
name: Quintana, Ester
name: Robles, René
name: Sánchez-López, Antonio
name: Arroyo, Rafael
name: Alvarez-Cermeño, Jose C
name: Vidal-Jordana, Angela
name: Malhotra, Sunny
name: Fissolo, Nicolas
name: Montalban, Xavier
name: Comabella, Manuel
Publisher: name: BioMed Central
Year: 2018

description: Background: It remains unclear whether disease course in multiple sclerosis (MS) is influenced by genetic polymorphisms. Here, we aimed to identify genetic variants associated with benign and aggressive disease courses in MS patients. Methods: MS patients were classified into benign and aggressive phenotypes according to clinical criteria. We performed exome sequencing in a discovery cohort, which included 20 MS patients, 10 with benign and 10 with aggressive disease course, and genotyping in 2 independent validation cohorts. The first validation cohort encompassed 194 MS patients, 107 with benign and 87 with aggressive phenotypes. The second validation cohort comprised 257 patients, of whom 224 patients had benign phenotypes and 33 aggressive disease courses. Brain immunohistochemistries were performed using disease course associated genes antibodies. Results: By means of single-nucleotide polymorphism (SNP) detection and comparison of allele frequencies between patients with benign and aggressive phenotypes, a total of 16 SNPs were selected for validation from the exome sequencing data in the discovery cohort. Meta-analysis of genotyping results in two validation cohorts revealed two polymorphisms, rs28469012 and rs10894768, significantly associated with disease course. SNP rs28469012 is located in CPXM2 (carboxypeptidase X, M14 family, member 2) and was associated with aggressive disease course (uncorrected p value &lt; 0.05). SNP rs10894768, which is positioned in IGSF9B (immunoglobulin superfamily member 9B) was associated with benign phenotype (uncorrected p value &lt; 0.05). In addition, a trend for association with benign phenotype was observed for a third SNP, rs10423927, in NLRP9 (NLR family pyrin domain containing 9). Brain immunohistochemistries in chronic active lesions from MS patients revealed expression of IGSF9B in astrocytes and macrophages/microglial cells, and expression of CPXM2 and NLRP9 restricted to brain macrophages/microglia. Conclusions: Genetic variants located in CPXM2, IGSF9B, and NLRP9 have the potential to modulate disease course in MS patients and may be used as disease activity biomarkers to identify patients with divergent disease courses. Altogether, the reported results from this study support the influence of genetic factors in MS disease course and may help to better understand the complex molecular mechanisms underlying disease pathogenesis.